Skip to main content

Table 4 Seroprotection and seroconversion

From: Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study

  All patients
(n = 226)
% (na/Nb)
bDMARDs monotherapy
(n = 80)
% (na/Nb)
bDMARDs + DMARDs
(n = 110)
% (na/Nb)
Rituximab
(n = 5)
% (na/Nb)
Systemic disorders (except Rituximab)
(n = 18)
% (na/Nb)
Other
(n = 13)
% (na/Nb)
Controls
(n = 15)
% (na/Nb)
A/Cal H1N1pdm09
 Seroprotection
  Pre-vaccine 40 97.0 (196/202) 97.2 (70/72) 96.9 (94/97) 100 (4/4) 100 (17/17) 91.7 (11/12) 100 (11/11)
  Post-vaccine 40 98.9 (196/198) 100 (66/66) 98.9 (98/99) 100 (5/5) 100 (17/17) 90.9 (10/11) 100 (13/13)
  p-valuec 0.10 - 0.16 - - 1.0 -
  Pre-vaccine 110 43.6 (88/202) 54.2 (39/72) 35.1 (34/97) 50.0 (2/4) 47.1 (8/17) 41.7 (5/12) 72.7 (8/11)
  Post-vaccine 110 65.2 (129/198) 63.6 (42/66) 66.7 (66/99) 40.0 (2/5) 58.8 (10/17) 81.8 (9/11) 84.6 (11/13)
  p-valuec < 0.0001* 0.05 < 0.0001* - 0.16 0.01 0.16
 Seroconversion 21.8 (38/174) 13.8 (8/58) 27.9 (24/86) 0 (0/4) 12.5 (2/16) 40.0 (4/10) 33.3 (3/9)
A/Swi H3N2
 Seroprotection
  Pre-vaccine 40 93.1 (188/202) 93.1 (67/72) 93.8 (91/97) 100 (4/4) 82.4 (14/17) 100 (12/12) 90.9 (10/11)
  Post-vaccine 40 97.5 (193/198) 98.5 (65/66) 96.9 (96/99) 100 (5/5) 94.1 (16/17) 100 (11/11) 100 (13/13)
  p-valuec 0.0016* 0.045 0.045 - 0.16 - -
  Pre-vaccine 110 14.9 (30/202) 15.3 (11/72) 13.4 (13/97) 25.0 (1/4) 11.8 (2/17) 25.0 (3/12) 18.2 (2/11)
  Post-vaccine 110 31.3 (62/198) 34.9 (23/66) 28.3 (28/99) 40.0 (2/5) 29.4 (5/17) 36.4 (4/11) 84.6 (11/13)
  p-valuec < 0.0001* 0.006* 0.0002* - 0.16 0.16 0.01
 Seroconversion 18.4 (32/174) 15.5 (9/58) 19.8 (17/86) 25.0 (1/4) 18.8 (3/16) 20.0 (2/10) 66.7 (6/9)
B/Phu Yamagata
 Seroprotection
  Pre-vaccine 40 97.0 (196/202) 95.8 (69/72) 97.9 (95/97) 75.0 (3/4) 100 (17/17) 100 (12/12) 100 (11/11)
  Post-vaccine 40 100 (198/198) 100 (66/66) 100 (99/99) 100 (5/5) 100 (17/17) 100 (11/11) 100 (13/13)
  p-valuec - - - - - - -
  Pre-vaccine 110 17.8 (36/202) 18.1 (13/72) 14.4 (14/97) 50.0 (2/4) 29.4 (5/17) 16.7 (2/12) 18.2 (2/11)
  Post-vaccine 110 19.7 (39/198) 15.2 (10/66) 17.2 (17/99) 40.0 (2/5) 35.3 (6/17) 36.4 (4/11) 53.9 (7/13)
  p-valuec 0.35 0.71 0.26 0.32 0.16 0.32 0.045
 Seroconversion 6.9 (12/174) 5.2 (3/58) 5.8 (5/86) 50.0 (2/4) 6.3 (1/16) 10.0 (1/10) 22.2 (29)
  1. Abbreviations: DMARDs disease modifying antirheumatic drugs; bDMARDs biological DMARDs
  2. aFor seroprotection, number of patients with antibody level above threshold. For seroconversion, number fulfilling the criteria for seroconversion. bTotal number of patients with available blood sample
  3. cThe proportion of children increasing to a protective level of antibodies was analysed using McNemars test. Only children with both pre-vaccine and post-vaccine blood samples were included in the analyses. The calculation of the p-value was not possible when one of the proportions was 100 %
  4. *Only p-values < 0.007 = 0.05/7 were considered statistically significant after Bonferroni correction for multiple testing for each outcome and each cut off
\